136 related articles for article (PubMed ID: 22959895)
1. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.
Férir G; Hänchen A; François KO; Hoorelbeke B; Huskens D; Dettner F; Süssmuth RD; Schols D
Virology; 2012 Nov; 433(2):308-19. PubMed ID: 22959895
[TBL] [Abstract][Full Text] [Related]
2. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
3. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
[TBL] [Abstract][Full Text] [Related]
4. Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.
Balzarini J; Van Laethem K; Daelemans D; Hatse S; Bugatti A; Rusnati M; Igarashi Y; Oki T; Schols D
J Virol; 2007 Jan; 81(1):362-73. PubMed ID: 17050611
[TBL] [Abstract][Full Text] [Related]
5. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.
Tintori C; Selvaraj M; Badia R; Clotet B; Esté JA; Botta M
ChemMedChem; 2013 Mar; 8(3):475-83. PubMed ID: 23404750
[TBL] [Abstract][Full Text] [Related]
6. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
Barbouche R; Decroly E; Kieny MP; Fenouillet E
Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
8. Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1.
Hoorelbeke B; Xue J; LiWang PJ; Balzarini J
PLoS One; 2013; 8(5):e64132. PubMed ID: 23741304
[TBL] [Abstract][Full Text] [Related]
9. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120.
Chiba H; Inokoshi J; Nakashima H; Omura S; Tanaka H
Biochem Biophys Res Commun; 2004 Mar; 316(1):203-10. PubMed ID: 15003531
[TBL] [Abstract][Full Text] [Related]
10. Effect of polyanion-resistance on HIV-1 infection.
Bobardt MD; Armand-Ugón M; Clotet I; Zhang Z; David G; Este JA; Gallay PA
Virology; 2004 Aug; 325(2):389-98. PubMed ID: 15246277
[TBL] [Abstract][Full Text] [Related]
11. Specific CD4 down-modulating compounds with potent anti-HIV activity.
Vermeire K; Schols D
J Leukoc Biol; 2003 Nov; 74(5):667-75. PubMed ID: 12960237
[TBL] [Abstract][Full Text] [Related]
12. Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.
Balzarini J; François KO; Van Laethem K; Hoorelbeke B; Renders M; Auwerx J; Liekens S; Oki T; Igarashi Y; Schols D
Antimicrob Agents Chemother; 2010 Apr; 54(4):1425-35. PubMed ID: 20047920
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV-1 entry: multiple keys to close the door.
Hertje M; Zhou M; Dietrich U
ChemMedChem; 2010 Nov; 5(11):1825-35. PubMed ID: 20845361
[No Abstract] [Full Text] [Related]
14. [Virtual screening of small molecular HIV-1 entry inhibitor NC-2 targeting gp120 and its action mechanism].
Duan H; Wang Y; Song D; Chen Z; Qiu J; Lu L; Jiang S; Liu S; Tan S
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):826-31. PubMed ID: 23803191
[TBL] [Abstract][Full Text] [Related]
15. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
16. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
[TBL] [Abstract][Full Text] [Related]
17. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein.
Li H; Song H; Heredia A; Le N; Redfield R; Lewis GK; Wang LX
Bioconjug Chem; 2004; 15(4):783-9. PubMed ID: 15264865
[TBL] [Abstract][Full Text] [Related]
18. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
Neffe AT; Meyer B
Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
[No Abstract] [Full Text] [Related]
19. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
20. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
